Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.

Archives of Iranian medicine - 1 Sept 2010

Zendehdel Nader, Biramijamal Firouzeh, Hossein-Nezhad Arash, Zendehdel Nasrin, Sarie Hamidreza, Doughaiemoghaddam Masoud, Pourshams Akram

Abstract excerpt

BACKGROUND: There are different clinical responses to omeprazole treatment in Iranian patients with gastroesophageal reflux disease. Omeprazole is metabolized in the liver by the cytochrome p450 2c19 (CYP2C19) enzyme. Two common polymorphisms of the CYP2C19 gene affect CYP2C19 enzyme activity. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Ulcer Agents
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Gastroesophageal Reflux

Share to Multivariate Analysis

Share to Omeprazole

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 20804307
DOI: 010135/AIM.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20804307-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.PMID 20804307Read ↗

Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.Semantic proximity Read ↗

Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.Semantic proximity Read ↗

A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.Semantic proximity Read ↗

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.Semantic proximity Read ↗

Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.Semantic proximity Read ↗

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.Semantic proximity Read ↗

Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.Semantic proximity Read ↗

Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia.Semantic proximity Read ↗

CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.